Koto R, Nakajima A, Horiuchi H, et al. - Using the JMDC Claims Database, this retrospective cohort study was conducted to determine the potential advantages of serum uric acid levels (sUA) control for preventing gout flare in individuals with asymptomatic hyperuricaemia. Overall 19,261 eligible people were analyzed. For both gout and asymptomatic hyperuricaemia, fewer occurrences of gout flare were reported in patients who achieved sUA ≤6.0 mg/dL with urate-lowering therapy (ULT) compared with patients whose sUA remained >6.0 mg/dL or who were not receiving ULT. Thus, it was evident that controlling sUA at ≤6.0 mg/dL resulted in decreased occurrences of gout flare among participants with asymptomatic hyperuricaemia as well as in those with gout.